New Drug Shows Promise in Breaking the Vicious Cycle of C. difficile Infections

BOULDER, CO – March 09, 2026 – A novel antibiotic candidate has demonstrated a remarkable ability to not only cure the dangerous intestinal infection Clostridioides difficile (CDI) but also to prevent its debilitating recurrence, a breakthrough that could reshape treatment for one of the nation's most urgent public health threats. The positive data for the drug, CRS3123, comes from Boulder-based Crestone, Inc., which announced the publication of its Phase 2 clinical trial results in the prestigious journal The Lancet Infectious Diseases.

The study shows that CRS3123 is as effective as the standard antibiotic, vancomycin, in achieving an initial clinical cure. However, its true promise lies in its success at preventing the infection from returning—a common and dangerous hallmark of CDI. Patients treated with CRS3123 had a recurrence rate of just 4%, a dramatic reduction compared to the 23% rate observed in patients treated with vancomycin.

CDI is the most common hospital-acquired infection in the U.S., responsible for nearly half a million infections and 30,000 deaths annually. The infection causes severe diarrhea and can lead to life-threatening inflammation of the colon. For many, the misery doesn't end after a single course of treatment, with 20% to 40% of patients experiencing a recurrence that can lead to a demoralizing cycle of repeated illness, hospitalization, and increased mortality.

A New Strategy Against a Stubborn Foe

The challenge with treating CDI has long been a paradox: the very antibiotics used to kill C. difficile often wipe out the beneficial bacteria in the gut, creating a barren landscape where any surviving C. difficile spores can germinate and cause a new infection. The Crestone trial was designed to test a more precise strategy.

In the Phase 2 study, which enrolled 43 patients across the U.S. and Canada, CRS3123 achieved a clinical cure in 97% of patients, on par with vancomycin's 93% cure rate. But the key difference emerged in the following weeks. At the 40-day mark, only one patient out of 29 in the combined CRS3123 groups had a recurrence, compared to three out of 14 in the vancomycin group.

“There are a lot of people who suffer from CDI repeatedly,” stated Dr. Thomas Louie of the University of Calgary, the study's principal investigator, in the company's press release. “It is essential that we improve patient access to clinical trials of new, more selective investigational agents like CRS3123 and to speed the development and approval of therapeutic options to avoid recurrences of CDI.”

Preserving the Body's Natural Defenses

The superior performance of CRS3123 appears to stem from its innovative mechanism. Unlike broad-spectrum antibiotics, CRS3123 is a narrow-spectrum agent that selectively inhibits a key enzyme in C. difficile, blocking its growth and toxin production while leaving most of the healthy gut microbiome unharmed.

This microbiome-sparing effect was confirmed through advanced multi-omics analysis of patient samples. The data showed that CRS3123 treatment preserved the diversity of the gut ecosystem, including beneficial bacteria like Bacteroides and Bifidobacterium. In contrast, patients treated with vancomycin showed a significant disruption, with their gut communities shifting toward a dominance of potentially harmful Enterobacteriaceae.

Furthermore, CRS3123 preserved the gut's ability to produce secondary bile acids, which are crucial for preventing C. difficile spores from germinating into active, toxin-producing bacteria. In an additional significant finding, the drug rapidly eliminated Vancomycin-resistant enterococci (VRE), another dangerous hospital-acquired pathogen, in patients who carried it, while VRE levels increased in the vancomycin group.

A Federally-Backed Push to the Finish Line

The development of CRS3123 has been significantly bolstered by a public-private partnership with the U.S. government. The Phase 2 trial and subsequent analyses were funded under a contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. This federal backing underscores the public health priority of finding better treatments for antibiotic-resistant infections.

Based on the promising initial results, NIAID exercised an option to fund a suite of projects to prepare CRS3123 for late-stage development. Crestone has since successfully improved its manufacturing process to reduce costs, confirmed the drug's stability for over five years, and completed critical nonclinical safety studies with no significant findings.

Reflecting its potential to address an unmet medical need, the FDA has granted CRS3123 both Qualified Infectious Disease Product (QIDP) and Fast Track designations. These programs are designed to accelerate the development and review of new drugs for serious infections, potentially shortening the timeline to get the therapy to patients and granting additional market exclusivity upon approval.

This combination of strong clinical data, a clear scientific advantage, and robust federal support has generated significant optimism. “Taken together, these data suggest CRS3123 could become the leading option for treating CDI,” said Dr. Nebojsa Janjic, CEO of Crestone. The company is now actively planning for larger Phase 3 trials, having already engaged with leaders at over 50 infectious disease centers worldwide to optimize the study designs. With its unique ability to both treat the initial infection and safeguard against its return, CRS3123 is poised to become a critical new tool in the ongoing battle against this persistent and dangerous pathogen.